Egr-1: A Target for Scleroderma Therapy PDF Print E-mail
Monday, 26 April 2010 15:10
Two separate research groups funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have discovered that the molecule EGR-1 (early growth response 1), which regulates gene expression, plays a central role in the development of fibrosis, a condition in which organ-supporting tissue becomes thick, hard, and rigid, hindering normal tissue and organ function. Controlling EGR-1, say the scientists, could be a potential therapy for such disorders as Scleroderma and pulmonary fibrosis. Their findings have been reported in the American Journal of Pathology.

Fibrosis is a disorder of the extracellular matrix, the mesh of proteins like collagen that makes up the body’s connective tissue. It is a factor in scleroderma, among other diseases, and can affect many of the body’s organs, including the lungs, liver, and skin. Its consequences can be devastating, even leading to death. Recent research has shown that cells in fibrotic tissue receive the wrong molecular signals, causing too many extracellular proteins to be made. One possible way to approach the fibrosis problem, scientists say, might be to try to interrupt such signals at critical points in the cellular pathways that they travel.

The two research groups, headed by Carol Feghali-Bostwick, Ph.D., at the University of Pittsburgh School of Medicine and John Varga, M.D ., at Northwestern University’s Feinberg School of Medicine, took separate approaches in discovering the importance of EGR-1. The University of Pittsburgh group induced fibrosis in mouse and human fibroblasts (cells that make up the extracellular matrix) by utilizing a signaling protein called IGFBP-5 (insulin-like growth factor binding protein 5). The Northwestern team administered the antibiotic bleomycin to induce scleroderma in mice. Both research teams found that the experimentally produced fibrosis was associated with abnormally elevated EGR-1 activity.

Furthermore, when they produced fibrosis in cells or in mice lacking EGR-1, the amounts of fibrosis were dramatically reduced. In further support of the findings, the Pittsburgh group found that EGR-1 levels were higher in lung tissues and fibroblasts of people with pulmonary fibrosis compared to controls. EGR-1, concluded the scientists, appears to be essential for the development of fibrosis, making it a potential target for therapy. The two studies also showed that independent signaling pathways, such as those for IGFBP-5 and bleomycin, both converge on EGR-1 to create fibrosis.

Fibrosis is a common disorder and a serious complication of many diseases. It is still considered hard to treat, with no currently approved therapies. Because the understanding of fibrosis is a major unmet medical need, any fresh insights into the disease process might open the door for novel therapies.

Source: 7th Space
 
More articles :

» Methotrexate Effective In Juvenile Localized Scleroderma

is effective in when given with a short course of steroids, an Italian randomized study confirmed.Among children ages 6 to 17 receiving methotrexate, 67.4% completed the yearlong trial without flaring, compared with 29.2% of those given placebo...

» Pulmonary Hypertension In Systemic Sclerosis

A.J. MacGregor, R. Canavan, C. Knight, C.P. Denton, J. Davar, J. Coghlan, and C.M. BlackPublished: 2001

» Study Suggests Systemic Sclerosis Is an Independent Risk Factor for Atherosclerosis

A new study by researchers in Hong Kong suggests that is an independent determinant for moderate to severe coronary calcification or . Conventional cardiovascular risk factors such as age and hypertension predispose patients with systemic sclerosis...

» Scleroderma May Be Initated By Cancer

has reported that researchers at have discovered that some cases of are likely to have been initiated by Cancer.  In a landmark paper published in Science, researchers focusing on a select group of patients with both Scleroderma and Cancer,...

» Biomarker Shows Promise In Scleroderma

A biomarker that can be used to screen patients for has shown promise in a proof of concept study. Researchers from St Vincent’s in Melbourne found (ADMA) levels had an acceptable high specificity and sensitivity for detecting the complication,...

» Facing Life's Challenges

At 57 years of age Anne Wersching doesn’t have a single wrinkle on her face.Sitting in her lounge room in Bayswater North, Ms Wersching looks well, save for a few red marks on her cheeks.But Ms Wersching has a little-known disease called...

Comments  

 
+1 #2 Nia 2012-09-16 23:51
i hve sd, very grateful for this research. wouldnt be suprised if there's a vaccine for autoimmune doseases in the not too distant future.
Report to administrator
 
 
+1 #1 Nia 2012-09-16 23:50
Quote:
exciting!
didnt know SD could be induced with an antibiotic...
Report to administrator